These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 14509872

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Oral candidosis and oral hairy leukoplakia as predictors of HAART failure in Brazilian HIV-infected patients.
    Miziara ID, Weber R.
    Oral Dis; 2006 Jul; 12(4):402-7. PubMed ID: 16792726
    [Abstract] [Full Text] [Related]

  • 23. Evaluating health-related wellbeing outcomes among outpatient adults with human immunodeficiency virus infection in the HAART era.
    Saunders DS, Burgoyne RW.
    Int J STD AIDS; 2002 Oct; 13(10):683-90. PubMed ID: 12396538
    [Abstract] [Full Text] [Related]

  • 24. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.
    Boschi A, Tinelli C, Ortolani P, Moscatelli G, Morigi G, Arlotti M.
    AIDS; 2004 Dec 03; 18(18):2381-9. PubMed ID: 15622314
    [Abstract] [Full Text] [Related]

  • 25. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 26. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.
    Antivir Ther; 2003 Oct 01; 8(5):379-84. PubMed ID: 14640384
    [Abstract] [Full Text] [Related]

  • 27. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
    Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, Abo Y, Salamon R, Bissagnene E, Seyler C, Eholié S, Anglaret X.
    AIDS; 2007 Nov 30; 21(18):2483-91. PubMed ID: 18025885
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S.
    Pediatrics; 2007 Oct 30; 120(4):e856-61. PubMed ID: 17846147
    [Abstract] [Full Text] [Related]

  • 29. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM, Araneta MR, Deville JG, Spector SA.
    Clin Infect Dis; 2004 Sep 01; 39(5):725-31. PubMed ID: 15356789
    [Abstract] [Full Text] [Related]

  • 30. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH, Chan KC, Lee SS.
    Clin Infect Dis; 2004 Sep 15; 39(6):853-60. PubMed ID: 15472819
    [Abstract] [Full Text] [Related]

  • 31. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S, Alary M.
    HIV Med; 2009 Nov 15; 10(10):640-6. PubMed ID: 19659945
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Predicting hospitalization among HIV-infected antiretroviral naïve patients starting HAART: determining clinical markers and exploring social pathways.
    Fielden SJ, Rusch ML, Levy AR, Yip B, Wood E, Harrigan RP, Goldstone I, Guillemi S, Montaner JS, Hogg RS.
    AIDS Care; 2008 Mar 15; 20(3):297-303. PubMed ID: 18351476
    [Abstract] [Full Text] [Related]

  • 34. An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART.
    Jelsma J, Maclean E, Hughes J, Tinise X, Darder M.
    AIDS Care; 2005 Jul 15; 17(5):579-88. PubMed ID: 16036244
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Antiretroviral treatment and quality of life in Africans living with HIV: 12-month follow-up in Burkina Faso.
    Jaquet A, Garanet F, Balestre E, Ekouevi DK, Azani JC, Bognounou R, Dah E, Kondombo JC, Dabis F, Drabo J.
    J Int AIDS Soc; 2013 Dec 18; 16(1):18867. PubMed ID: 24369739
    [Abstract] [Full Text] [Related]

  • 37. Measuring quality of life in rural Uganda: reliability and validity of summary scores from the medical outcomes study HIV health survey (MOS-HIV).
    Stangl AL, Bunnell R, Wamai N, Masaba H, Mermin J.
    Qual Life Res; 2012 Nov 18; 21(9):1655-63. PubMed ID: 22198741
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Self-reported symptoms among HIV-lnfected patients on highly active antiretroviral therapy in the ATHENA cohort in The Netherlands.
    de Boer IM, Prins JM, Sprangers MA, Smit C, Nieuwkerk PT.
    HIV Clin Trials; 2011 Nov 18; 12(3):161-70. PubMed ID: 21684856
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.